	US 12,275,949 B2
	High-transducing HSV vectors
David M. Krisky, Pittsburgh, PA (US); James B. Wechuck, Pittsburgh, PA (US); and James R. Goss, Pittsburgh, PA (US)
Assigned to PeriphaGen, Inc., Pittsburgh, PA (US)
Filed by PeriphaGen, Inc., Pittsburgh, PA (US)
Filed on Jul. 26, 2023, as Appl. No. 18/359,013.
Application 18/359,013 is a division of application No. 16/088,393, granted, now 11,753,653, previously published as PCT/US2017/024092, filed on Mar. 24, 2017.
Claims priority of provisional application 62/313,391, filed on Mar. 25, 2016.
Prior Publication US 2024/0158809 A1, May 16, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. C12N 15/86 (2006.01); A61K 48/00 (2006.01); C12N 7/00 (2006.01)

CPC C12N 15/86 (2013.01) [A61K 48/0025 (2013.01); C12N 7/00 (2013.01); C12N 2710/16621 (2013.01); C12N 2710/16643 (2013.01); C12N 2710/16662 (2013.01); C12N 2830/008 (2013.01)]

14 Claims

1. A gene therapy vector comprising a replication-defective variant of herpes simplex virus (HSV) McKrae strain whose genome contains an alteration such that the variant fails to express a functional ICP4 protein comprising SEQ ID NO: 16, wherein the gene therapy vector is capable of expressing a payload in a cell susceptible to McKrae strain infection for at least 18 days.